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Mixed Cryptosporidium infections were detected in 7 of
21 patients with a diagnosis of rare Cryptosporidium canis
or  C. felis infections; 6 patients were infected with 2
Cryptosporidium spp. and 1 patient with 3 species. Mixed
infections may occur more frequently than previously
believed and should be considered when assessing cryp-
tosporidiosis. 
C
ryptosporidium spp. infect humans and other verte-
brate animals. Persons with compromised immune
systems can suffer life-threatening chronic diarrhea, espe-
cially when their CD4+ lymphocyte counts fall <200
cells/µL. At least 7 Cryptosporidium spp. have been
detected in immunocompromised patients (1).
Nonetheless, the role of concurrent or mixed infections in
the pathogenesis and transmission of Cryptosporidium
spp. is unclear. Mixed infections of Cryptosporidium
hominis and  C. parvum have been reported in several
patients from Switzerland and England (2,3). Additional
studies from the United Kingdom reported simultaneous
infections with these 2 species: 4 cases in 2 waterborne
outbreaks and 2 cases of sporadic infections from 1995 to
1999 (4). In a more recent study, 12% of 135 clinical spec-
imens from Aberdeenshire, Scotland, had concurrent C.
parvum and  C. hominis infections (5). Mixed C.
hominis–C. parvum infections were also seen in 2 of 38
archived human specimens in a study conducted in the
United States (6). These observations suggest that mixed
Cryptosporidium infections are not uncommon.
Mixed infections may not be readily identified by com-
monly used molecular diagnostic tools because of prefer-
ential polymerase chain reaction (PCR) amplification of
the predominant genotypes or the specificity of molecular
tools (6). For example, PCR–restriction fragment length
polymorphism (RFLP) tools based on the small subunit
(SSU) rRNA gene are frequently used in genotyping
Cryptosporidium spp. because they have higher sensitivity
and detect more species than PCR-RFLP tools based on
other genes (7).
Two previous studies in Peru used an SSU-rRNA–based
PCR-RFLP tool to genotype Cryptosporidium specimens
from children (8) and AIDS patients (1). A variety of
Cryptosporidium spp. were found in both patient popula-
tions; C. hominis was the predominant species, followed by
C. parvum, C. meleagridis, C. canis, and C. felis, but mixed
infections were rarely detected (1,8). However, a recent
study of some of the specimens that used PCR tools that
selectively amplify DNA of C. parvum and closely related
species identified concurrent infections of C. hominis in
specimens previously diagnosed as having only C. canis, C.
muris, or C. suis (7). Another recent study has shown that
an SSU rRNA–based PCR-RFLPtool had only a 31%–74%
success rate in detecting concurrent infections with C.
parvum and C. hominis (9). 
The Study
We addressed the question of whether Peruvian HIV-
positive patients infected with the usual C. canis or C. felis
parasites were co-infected with C. hominis, C. parvum, or
C. meleagridis (7). The study protocol was approved by
the participating institutional review boards. All partici-
pants gave written informed consent.
Mixed infections were identified by using 2 PCR-RFLP
tools that only amplify C. hominis,  C. parvum, or C.
meleagridis (7). One tool was based on the dihydrofolate
reductase (DHFR) gene (10) and the other on the
Cryptosporidium oocyst wall protein (COWP) gene (11).
Fifty-six stool specimens from 21 HIV-infected persons
with previous diagnoses of C. canis or C. felis with an SSU
rRNA–based PCR-RFLP tool were re-analyzed with these
2 molecular tools. DNA was extracted by using the
QIAamp stool DNA extraction kit (Qiagen Inc., Valencia,
CA, USA), and 1 µL DNA was used in nested PCR analy-
ses of the DHFR and COWP genes. Secondary PCR prod-
ucts positive for Cryptosporidium were digested with
restriction enzymes BpuA I for the DHFR tool or Rsa I for
the COWP tool (10,11). Results of RFLP diagnosis were
confirmed by DNA sequence analysis. All secondary PCR
products were sequenced with a 3100 ABIPrism Genetic
Analyzer (Applied Biosystems, Foster City, CA, USA).
The sequences obtained were aligned with reference
sequences from GenBank by using BioEdit version 7.0.5
(Isis Pharmaceuticals, Carlsbad, CA, USA).
The PCR analysis of both DHFR and COWP genes
showed that 17 specimens from 7 patients yielded products
of the expected size for Cryptosporidium spp. (Figure,
panel A, and Table). Restriction analysis of DHFR prod-
ucts with BpuA I showed that 4 patients had banding pat-
terns indicative of C. hominis, 1 patient had the pattern of
C. parvum, 1 patient had the pattern of C. meleagridis, and
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(Figure panel B). Likewise, RFLP analysis of the COWP
PCR products digested with Rsa I showed 3 banding pat-
terns that were in complete agreement with the results
obtained for the DHFR PCR-RFLP tool (Figure panel C).
Therefore, 2 of the 12 C. canis–infected patients had C.
hominis, 1 had C. parvum and 1 had both C. hominis and
C. meleagridis; of the 9 C. felis-infected patients, 2 had C.
hominis and 1 had C. meleagridis (Table). 
All DHFR and COWP PCR products were sequenced,
which confirmed the results of the RFLP diagnosis.
Altogether, 8, 2, and 3 DHFR sequences were obtained for
C. hominis, C. parvum, and C. meleagridis, respectively.
The C. hominis and C. meleagridis DHFR sequences were
identical to XM_660774 and AY391725, respectively. The
C. parvum DHFR sequences were homologous to
XM_625460, with an insertion at position 37 and 4 bp sub-
stitutions at positions 66, 69, 364, and 367. Likewise, 10,
2, and 3 COWP sequences were obtained for C. hominis,
C. parvum, and C. meleagridis, respectively, and were
identical to AF481960, AF266273, and AY166840, respec-
tively, in GenBank. The C. parvum DHFR nucleotide
sequence obtained from this study is deposited in GenBank
under accession no. DQ352814.
To confirm the original diagnosis of C. canis and C.
felis infection, we reanalyzed all DNA preparations of
these specimens with the SSU rRNA genotyping tool (7).
Results were in complete agreement with those obtained
previously (7): 19 specimens from 12 patients had C.
canis, 15 specimens from 9 patients had C. felis, and no
specimens had mixed Cryptosporidium spp., as indicated
by RFLP patterns (Table and Figure panel D). 
Data on diarrhea at study enrollment were available for
4 of the 7 patients with mixed infections and all 14 patients
without mixed infections. Among persons with mixed
infections, 1 did not have diarrhea, 2 had diarrhea lasting
<30 days, and 1 had diarrhea >5 months. Seven of 14
patients without mixed infections had diarrhea: 5 had acute
diarrhea lasting <30 days, and 2 had chronic diarrhea last-
ing >5 months (difference in prevalence of diarrhea for
mixed versus single infections was not significant by the
Fisher exact test). The average CD4+ lymphocyte count
among the patients with mixed infections was 130 cells/µL.
Of the 7 patients with mixed infections, 3 had specimens
collected >30 days after the first detection, and mixed
infections with the same species were still identified. The
persistence of 2 species for >1 month is in contrast to a
report that 1 Cryptosporidium genotype rapidly displaces
the other during experimental infections of animals (6). 
Conclusions
Concurrent infection with multiple Cryptosporidium
spp. may affect clinical manifestations since C. hominis
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Figure. Multilocus polymerase chain reaction–restriction fragment
length polymorphism (PCR-RFLP) analysis of specimens previ-
ously identified as Cryptosporidium canis and C. felis. A) Agarose
gel electrophoresis of PCR-amplified products of specimens previ-
ously identified as C. canis (lanes 1–3) and C. felis (lanes 4 and 5)
with molecular tools based on the small subunit (SSU) rRNA, dihy-
drofolate reductase (DHFR), and Cryptosporidium oocyst wall pro-
tein (COWP). Molecular markers in all photos are 100-bp ladders.
B) RFLP analysis of DHFR-based PCR amplification products
using BpuA I restriction enzyme; lanes 1, 4, and 5 are C. hominis;
lane 2 is C. parvum; and lane 3 is C. meleagridis. C) RFLP analy-
sis of COWP-based PCR amplification products using Rsa I
restriction enzyme; lanes 1, 4, and 5 are C. hominis; lane 2 is C.
parvum; and lane 3 is C. meleagridis. D) RFLP analysis of the
SSU-based PCR products using restriction enzymes Ssp I (left)
and Vsp I (right); the combined patterns for lanes 1 to 3 corre-
spond to C. canis and lanes 4 and 5 to C. felis.and C. parvum induce different sequelae in humans (12).
The frequent finding of C. hominis in C. canis– and C.
felis–infected persons also raises the question of infection
sources. Although these 2 species are traditionally associ-
ated with animals, anthroponotic transmission may play a
role in their acquisition in humans. Recent analyses
demonstrate that a large proportion of human infections
with C. parvum, another traditional zoonotic species, are
actually due to anthroponotic transmission (13,14). 
Our results also suggest that although the SSU
rRNA–based PCR-RFLP tool or similar PCR techniques
can detect and differentiate a wide range of
Cryptosporidium species or genotypes, their usefulness in
detecting mixed infections was compromised by preferen-
tial PCR amplification of the dominant species or genotype
in specimens. This problem is likely inherited with most
PCR tools. Thus, the use of PCR tools with broad speci-
ficity in combination with species-specific tools is needed
to address the issue of mixed Cryptosporidium infections.
Our findings demonstrate that mixed infections are
more frequent and persist longer in HIV-infected patients
than previously believed. The clinical importance of these
findings is not clear because of the study’s cross-sectional
nature. Future studies should employ tools that can detect
mixed Cryptosporidium infections in longitudinal studies,
evaluate the frequency of mixed infections of C. hominis
and C. parvum, and assess their clinical and epidemiolog-
ic implications in both immunocompetent and immuno-
compromised persons.
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